Novartis agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz U.S. dermatology business and generic U.S. oral solids portfolio, to Aurobindo Pharma USA for $900 million in cash plus $100 million in potential earn-outs.
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
Sanofi reached a civil settlement with the U.S. Securities and Exchange Commission fully resolving the SEC’s investigation into possible violations of the U.S. Foreign Corrupt Practices Act.
Americans suffering from a “vacation deficit” are nearly two times as likely to show signs of moderately severe to severe depression compared to the national average, according to the 10th annual Allianz Global Assistance Vacation Confidence Index.
bluebird bio Inc. and Gritstone Oncology Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Sierra Oncology Inc. announced that the clinical-stage drug-development company acquired the drug candidate momelotinib from Gilead Sciences.
Syneos Health Inc. announced the acquisition of Kinapse – a market leading advisory and operational solutions provider to the global life sciences industry – from Hg, a specialist investor based in the U.K.
Gilead Sciences Inc. announced that Gregg Alton was appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, was promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, decided to leave Gilead to pursue another opportunity.
Outcome Health announced a partnership with the American Liver Foundation to raise awareness of liver disease, specifically hepatitis C.
Mustang Bio Inc. and St. Jude Children’s Research Hospital announced that they have partnered and entered into an exclusive worldwide license agreement for the development of a first-in-class ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“X-SCID”), also known as bubble boy disease.
